Impact of the COVID-19 Pandemic on Juvenile Idiopathic Arthritis Presentation and Research Recruitment: Results from the CAPRI Registry (135/140).

OBJECTIVE The COVID-19 pandemic has disrupted healthcare delivery and clinical research worldwide, with data from areas most affected demonstrating an impact on rheumatology care. This study aimed to characterize the impact of the pandemic on the initial presentation of JIA and JIA-related research in Canada. METHODS Data collected from the Canadian Alliance of Pediatric Rheumatology Investigators JIA Registry from the year pre-pandemic (March 11, 2019-March 10, 2020) was compared with data collected during the first year of the pandemic (March 11, 2020-March 10, 2021). Outcomes included time from symptom onset to first assessment, disease severity at presentation and registry recruitment. Proportions and medians were used to describe categorical and continuous variables, respectively. RESULTS The median time from symptom onset to first assessment was 138 days (IQR 64-365) pre-pandemic vs 146 days (IQR 83-359) during the pandemic. The JIA category frequencies remained overall stable, (44% oligoarticular JIA pre-pandemic, 46.8% pandemic), except for systemic JIA (12 cases pre-pandemic, 1 pandemic). Clinical features, disease activity (cJADAS10), disability (CHAQ) and quality of life (JAQQ) scores were similar between the two cohorts. Pre-pandemic, 225 patients were enrolled, compared with 111 in the pandemic year, with the greatest decrease from March to June 2020. CONCLUSIONS We did not observe the anticipated delay in time to presentation or increased severity at presentation, suggesting that, within Canada, care adapted well to provide support to new patient consults without negative impacts. The COVID-19 pandemic was associated with an initial 50% decrease in registry enrolment but has since improved.

[1]  C. Wouters,et al.  O31 Trajectories of anxiety in children young people and adults with rheumatic diseases in the wake of COVID-19: results from the COVID-19 European patient registry , 2021, Rheumatology (Oxford, England).

[2]  A. Alibrandi,et al.  Negative effect of lockdown on juvenile idiopathic arthritis patients , 2021, Clinical Rheumatology.

[3]  R. M. Beattie,et al.  The impact of national lockdown on nutritional status of children with inflammatory bowel disease. , 2021, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[4]  D. Pachito,et al.  Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review , 2021, JCO global oncology.

[5]  K. Iyengar,et al.  Impact of COVID-19 on rheumatology practice in the UK—a pan-regional rheumatology survey , 2021, Clinical Rheumatology.

[6]  N. Jones How COVID-19 is changing the cold and flu season , 2020, Nature.

[7]  A. Cicchetti,et al.  Impact of SARS-CoV-2 on Provided Healthcare. Evidence From the Emergency Phase in Italy , 2020, Frontiers in Public Health.

[8]  R. Rapee,et al.  Risk and Protective Factors for Prospective Changes in Adolescent Mental Health during the COVID-19 Pandemic , 2020, Journal of youth and adolescence.

[9]  R. Cimaz,et al.  Management of Juvenile idiopathic arthritis-associated uveitis duringthe COVID-19 pandemic in a pediatric referral center in Lombardy , 2020, Ocular immunology and inflammation.

[10]  Ş. Karadağ,et al.  Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19 , 2020, Rheumatology International.

[11]  D. Karp,et al.  American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1 , 2020, Arthritis & rheumatology.

[12]  A. Rosenberg,et al.  A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry. , 2020, Rheumatology.

[13]  R. Schneider,et al.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis , 2019, Arthritis care & research.

[14]  K. Aalto,et al.  Validating 10-joint juvenile arthritis disease activity score cut-offs for disease activity levels in non-systemic juvenile idiopathic arthritis , 2019, RMD Open.

[15]  T. Loughin,et al.  Predicting Which Children with Juvenile Idiopathic Arthritis Will Have a Severe Disease Course: Results from the ReACCh-Out Cohort , 2017, The Journal of Rheumatology.